-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 1st, Jiudian Pharmaceutical rose rapidly during the session, rising by more than 2% within 5 minut.
In the morning, it rose by more than 7% to 242 yuan, a new high in 6 mont.
According to the data, Jiudian Pharmaceutical is one of the few domestic companies that takes transdermal drug delivery as a key strategic development directi.
The company's main business is the research and development, production and sales of pharmaceutical produc.
The products mainly include pharmaceutical preparations, APIs, and pharmaceutical excipien.
At the same time, the company will be driven by research and development and technology, and is committed to "pharmaceutical preparations + APIs + pharmaceutical excipients" integrated development, and make full use of the advantages of R&D and production accumulated in the industry to provide CXO services for related enterprises in the indust.
On July 29, the company's performance report for the first half of 2022 showed that the operating income during the reporting period was 031 billion yuan, a year-on-year increase of 489%; the net profit attributable to shareholders of the listed company was 130 million yuan, a year-on-year increase of 102%; The stock income is 39 yuan; the average return on equity ROE is 14
As of the end of the reporting period, the company's net assets were 177 billion yuan, an increase of 04% compared with the same period last year, and the asset-liability ratio was 38
The net cash flows from operating activities, investment activities and financing activities were 31431 million yuan, -18552 million yuan, and -66713 million yuan, down 441%, up 989%, and down 1239% year-on-ye.
As for the reasons for the growth in performance, the company said that it was mainly due to its continuous increase in the market promotion of its dominant product, Loxoprofen Sodium Gel Patch, and the continuous optimization of the production process of this produ.
The cost was well controlled and the scale effect became increasingly promine.
The report During the period, the sales revenue of this variety was 576 million yuan, a year-on-year increase of 5
In addition, the company's revenue mainly comes from pharmaceutical preparations, among which, the revenue of main products such as loxoprofen sodium gel patch, pantoprazole sodium preparation, and ornidazole preparation accounts for the proportion of main business income increasing year by year
It is worth mentioning that Jiudian Pharmaceutical also stated at the semi-annual report performance exchange conference call that most of the company's research and development efforts will focus on the research and development of transdermal drug delivery products, and the company is vigorously developing transdermal drug delivery preparations, including Gel patches, topical patches, systemic patches, gels and creams, e.
, there are more than 15 varieties under development, the proportion of generic drugs and improved new drugs is close, and the main indications are analgesia and elderly disease-based; at the same time, the company also has innovative drug projects under developme.
Behind the company's increased research and development, its research and development expenses have maintained a continuous growth tre.
Among them, in the first half of 2022 alone, the company's research and development expenses reached 891 million yuan, a year-on-year increase of 5
In the first half of 2022, the company's gross profit margin was 705%, basically the same as the same period last ye.
Debon Securities pointed out that under the influence of company expenses, the growth rate of profit in the first half of the year was lower than that of revenue, and the logic of high growth was still stro.
Maintain "Buy" rati.
Capital Securities released a research report saying that the increase in the company's expenses led to a slower growth rate of profits than the growth rate of revenue; Loxoprofen sodium gel patch continued to rapidly increase in volume under the influence of the epidemic, and the growth rate is expected to pick up in the second half of the ye.
A number of preparations have been selected for centralized procurement and are expected to maintain stable growth throughout the year; APIs and excipients have grown rapidly, and profitability has been further improv.
Give it a Buy rati.
In addition, Ping An Securities stated in the research report that in the first half of 2022, under the influence of adverse factors such as the epidemic, the company still achieved considerable performance grow.
The company focuses on the field of transdermal drug delivery, the market space is broad, the competition pattern is good, and the company has a clear leading advantage with its rich R&D pipeli.
In 2022, the centralized procurement of the core variety Loxoprofen Sodium Gel Patch will be launched, which will help the company to expand OTC channels, and is expected to be included in the new version of the Essential Drug Li.
The agency believes that the current valuation is still outstanding and maintains the "recommended" rati.
In the morning, it rose by more than 7% to 242 yuan, a new high in 6 mont.
According to the data, Jiudian Pharmaceutical is one of the few domestic companies that takes transdermal drug delivery as a key strategic development directi.
The company's main business is the research and development, production and sales of pharmaceutical produc.
The products mainly include pharmaceutical preparations, APIs, and pharmaceutical excipien.
At the same time, the company will be driven by research and development and technology, and is committed to "pharmaceutical preparations + APIs + pharmaceutical excipients" integrated development, and make full use of the advantages of R&D and production accumulated in the industry to provide CXO services for related enterprises in the indust.
On July 29, the company's performance report for the first half of 2022 showed that the operating income during the reporting period was 031 billion yuan, a year-on-year increase of 489%; the net profit attributable to shareholders of the listed company was 130 million yuan, a year-on-year increase of 102%; The stock income is 39 yuan; the average return on equity ROE is 14
As of the end of the reporting period, the company's net assets were 177 billion yuan, an increase of 04% compared with the same period last year, and the asset-liability ratio was 38
The net cash flows from operating activities, investment activities and financing activities were 31431 million yuan, -18552 million yuan, and -66713 million yuan, down 441%, up 989%, and down 1239% year-on-ye.
As for the reasons for the growth in performance, the company said that it was mainly due to its continuous increase in the market promotion of its dominant product, Loxoprofen Sodium Gel Patch, and the continuous optimization of the production process of this produ.
The cost was well controlled and the scale effect became increasingly promine.
The report During the period, the sales revenue of this variety was 576 million yuan, a year-on-year increase of 5
In addition, the company's revenue mainly comes from pharmaceutical preparations, among which, the revenue of main products such as loxoprofen sodium gel patch, pantoprazole sodium preparation, and ornidazole preparation accounts for the proportion of main business income increasing year by year
It is worth mentioning that Jiudian Pharmaceutical also stated at the semi-annual report performance exchange conference call that most of the company's research and development efforts will focus on the research and development of transdermal drug delivery products, and the company is vigorously developing transdermal drug delivery preparations, including Gel patches, topical patches, systemic patches, gels and creams, e.
, there are more than 15 varieties under development, the proportion of generic drugs and improved new drugs is close, and the main indications are analgesia and elderly disease-based; at the same time, the company also has innovative drug projects under developme.
Behind the company's increased research and development, its research and development expenses have maintained a continuous growth tre.
Among them, in the first half of 2022 alone, the company's research and development expenses reached 891 million yuan, a year-on-year increase of 5
In the first half of 2022, the company's gross profit margin was 705%, basically the same as the same period last ye.
Debon Securities pointed out that under the influence of company expenses, the growth rate of profit in the first half of the year was lower than that of revenue, and the logic of high growth was still stro.
Maintain "Buy" rati.
Capital Securities released a research report saying that the increase in the company's expenses led to a slower growth rate of profits than the growth rate of revenue; Loxoprofen sodium gel patch continued to rapidly increase in volume under the influence of the epidemic, and the growth rate is expected to pick up in the second half of the ye.
A number of preparations have been selected for centralized procurement and are expected to maintain stable growth throughout the year; APIs and excipients have grown rapidly, and profitability has been further improv.
Give it a Buy rati.
In addition, Ping An Securities stated in the research report that in the first half of 2022, under the influence of adverse factors such as the epidemic, the company still achieved considerable performance grow.
The company focuses on the field of transdermal drug delivery, the market space is broad, the competition pattern is good, and the company has a clear leading advantage with its rich R&D pipeli.
In 2022, the centralized procurement of the core variety Loxoprofen Sodium Gel Patch will be launched, which will help the company to expand OTC channels, and is expected to be included in the new version of the Essential Drug Li.
The agency believes that the current valuation is still outstanding and maintains the "recommended" rati.
